SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 Suppl III: iii818.
  • 2
    Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 44252.
  • 3
    Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 134956.
  • 4
    Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 166775.
  • 5
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594600.
  • 6
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002; 359: 118793.
  • 7
    Van der Heijde D, Djikmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 58291.
  • 8
    Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al, for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 213646.
  • 9
    Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC Jr, et al. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 2008; 35: 134653.
  • 10
    Stone MA, Payne U, Pacheco-Tena C, Inman RD. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004; 63: 847.
  • 11
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 66570.
  • 12
    Davis JC Jr, van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005; 32: 17514.
  • 13
    Burgos-Vargas R, Rojas-Serrano J. Predictors of response to tumor necrosis factor-α blockers in ankylosing spondylitis. J Rheumatol 2005; 32: 163740.
  • 14
    Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008; 67: 127681.
  • 15
    Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009; 36: 8018.
  • 16
    Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 56370.
  • 17
    Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8: R72.
  • 18
    Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, et al. TNFα antagonists continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007; 74: 14854.
  • 19
    Pavelka K, Forejtova S, Stolfa J, Chroust K, Buresova L, Mann H, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice: results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009; 27: 95863.
  • 20
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005; 64: 22934.
  • 21
    Luc M, Gossec L, Ruyssen-Witrand A, Salliot C, Duclos M, Guignard S, et al. C-reactive protein predicts tumor necrosis factor-α blocker retention rate in ankylosing spondylitis. J Rheumatol 2007; 34: 207881.
  • 22
    Geborek P, Crnkic M, Petersson IF, Saxne T, and the South Swedish Arthritis Treatment Group. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 7938.
  • 23
    Strombeck B, Jacobsson LT, Bremander A, Englund M, Heide A, Turkiewicz A, et al. Patients with ankylosing spondylitis have increased sick leave: a registry-based case-control study over 7 years. Rheumatology (Oxford) 2009; 48: 28992.
  • 24
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 25
    Svensk Reumatologisk Förening. 2010. URL: http://www.svenskreumatologi.se.
  • 26
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 27
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 28
    Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis: use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988; 17: 26371.
  • 29
    Stone MA, Inman RD, Wright JG, Maetzel A. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Rheum 2004; 51: 31620.
  • 30
    Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 187686.
  • 31
    Singh G, Lawrence A, Agarwal V, Misra R, Aggarwal A. Higher prevalence of extra-articular manifestations in ankylosing spondylitis with peripheral arthritis. J Clin Rheumatol 2008; 14: 2646.
  • 32
    Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T, et al. Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 2008; 27: 111925.
  • 33
    Baek HJ, Shin KC, Lee YJ, Kang SW, Lee EB, Yoo CD, et al. Clinical features of adult-onset ankylosing spondylitis in Korean patients: patients with peripheral joint disease (PJD) have less severe spinal disease course than those without PJD. Rheumatology (Oxford) 2004; 43: 152631.
  • 34
    Lee JH, Jun JB, Jung S, Bae SC, Yoo DH, Kim TY, et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci 2002; 17: 66973.
  • 35
    Khan MA, Kushner I, Braun WE. Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum 1977; 20: 90912.
  • 36
    Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36: 76671.
  • 37
    Vinje O, Dale K, Moller P. Radiographic evaluation of patients with Bechterew's syndrome (ankylosing spondylitis): findings in peripheral joints, tendon insertions and the pubic symphysis and relations to non-radiographic findings. Scand J Rheumatol 1985; 14: 27988.
  • 38
    Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43: 229.
  • 39
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, and the British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 155865.
  • 40
    Forslind K, Hafstrom I, Ahlmen M, Svensson B, and the BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007; 66: 4652.
  • 41
    Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009; 8: 4317.
  • 42
    Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47: 4959.
  • 43
    Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis: results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006; 8: R174.
  • 44
    Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008; 67: 3649.
  • 45
    Krishnan E, Fries JF. Measuring effectiveness of drugs in observational databanks: promises and perils. Arthritis Res Ther 2004; 6: 414.